Drug Profile
Rivastigmine transdermal - Teikoku Pharma USA
Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator Teikoku Pharma USA
- Class Antidementias; Phenylcarbamates; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors; Butyrylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 31 Aug 2023 Discontinued - Preclinical for Alzheimer's disease in USA (Transdermal) (Teikoku Pharma USA pipeline, August 2023).
- 28 Apr 2020 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Transdermal, Patch)
- 04 Mar 2016 Preclinical trials in Alzheimer's disease in USA (Transdermal) before March 2016